Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1479690 | 0.86 | ALDH1A1 (0.40) | CD44CYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL16660691 | 0.86 | CYP3A4 (0.46) | CD44CYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL29838774 | 0.86 | ALDH1A1 (0.40) | CD44CYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL832391 | 0.86 | CYP3A4 (0.60) | CD44CYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL1548535 | 0.86 | CYP3A4 (0.60) | CD44CYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL28606707 | 0.80 | CYP3A4 (0.60) | CD44CYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL317553 | 0.79 | CD44 (0.52) | CD44CYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL405019 | 0.79 | CYP3A4 (0.40) | CD44CYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL11378722 | 0.79 | ALDH1A1 (0.43) | CYP3A4TSHRMAPK1ALDH1A1ALOX15 | |
| SCHEMBL15515282 | 0.79 | CYP3A4 (0.46) | CD44CYP3A4TSHRMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362642-A | Polyimide with high Tg and low dielectric constant, and preparation method and application thereof | 中国科学院福建物质结构研究所 | 2024-01-09 | — | — | CN | disclosed |
| EP-4257591-A2 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| US-10576087-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2020-03-03 | — | — | US | disclosed |
| US-10576087-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2020-03-03 | — | — | US | disclosed |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-01-28 | — | — | US | disclosed |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-20190000857-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2019-01-03 | — | — | US | disclosed |
| EP-3124472-B1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE LTD (KY) | 2018-07-25 | — | — | EP | disclosed |
| EP-3124472-B1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE LTD (KY) | 2018-07-25 | — | — | EP | disclosed |
| US-9895376-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2018-02-20 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | CD44 4596/4885CYP3A4 114/4885TSHR 3828/4885 |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CD44 3749/4885CYP3A4 3093/4885TSHR 791/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | CD44 4693/4885CYP3A4 104/4885TSHR 4027/4885 |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | CD44 825/4885CYP3A4 2376/4885TSHR 82/4885 |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | CD44 3749/4885CYP3A4 3093/4885TSHR 791/4885 |
| US-20190000857-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CD44 3731/4885CYP3A4 3051/4885TSHR 3107/4885 |
| US-10576087-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BRAF, RAF1, ARAF | CD44 2941/4885CYP3A4 2432/4885TSHR 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.